SCHEMBL923368

SCHEMBL923368

Nc1cccc(CN2CCCCC2)c1

nearest known ligand 0.96

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.66
ALDH1A1 P00352 4/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
TDP1 Q9NUW8 1/20 0.64
KDM4E B2RXH2 1/20 0.58
GAA P10253 1/20 0.58
CYP2D6 P10635 2/20 0.57
CYP2C9 P11712 1/20 0.57
HIF1A Q16665 1/20 0.57
HRH3 Q9Y5N1 4/20 0.55
CYP2C19 P33261 1/20 0.55
SIGMAR1 Q99720 1/20 0.54
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
MBTD1 Q05BQ5 1/20 0.51
TP53BP1 Q12888 1/20 0.51
L3MBTL3 Q96JM7 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HRH4 Q9H3N8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566828 1.00 PRMT6 (0.66) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL30469295 0.98 PRMT6 (0.68) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL833409 0.98 PRMT6 (0.68) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL13242846 0.94 PRMT6 (0.62) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL16760957 0.90 SIGMAR1 (0.56) PRMT6ALDH1A1SMN1; SMN2TDP1SIGMAR1
SCHEMBL11339852 0.86 PRMT6 (0.78) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL11192726 0.86 PRMT6 (0.78) PRMT6ALDH1A1SMN1; SMN2TDP1KDM4E
SCHEMBL22538106 0.84 CHKA (0.63) PRMT6KDM4EHRH3SIGMAR1
SCHEMBL8879213 0.82 SIGMAR1 (0.62) PRMT6ALDH1A1TDP1CYP2C9HIF1A
SCHEMBL264786 0.82 NCF1 (0.71) PRMT6ALDH1A1SMN1; SMN2KDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190834-B1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2011-03-02 EP claimed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP claimed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US claimed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO claimed
CN-114235972-B Method for determining content of linagliptin impurity RBP-1 乳源东阳光药业有限公司 2023-08-22 CN disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
CN-111363732-B Transaminase mutant from aspergillus terreus NIH2624 and application thereof 卡柔恩赛生物技术湖北有限公司 2023-05-23 CN disclosed
CN-111363732-B Transaminase mutant from aspergillus terreus NIH2624 and application thereof 卡柔恩赛生物技术湖北有限公司 2023-05-23 CN disclosed
US-11289238-B2 Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2022-03-29 US disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed
US-6166006-A Anilide derivative, production and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-12-26 US disclosed
EP-1039899-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
EP-1040103-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-10-04 EP disclosed
US-6028081-A TREATING PEPTIC ULCERS SSP CO., LTD. (JP) 2000-02-22 US disclosed
WO-1999032100-A2 PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
WO-1999032468-A1 ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-07-01 WO disclosed
EP-0900789-A2 Substituted quinolone derivatives and pharmaceuticals containing the same SSP Co., Ltd. (JP) 1999-03-10 EP disclosed
EP-0313393-A2 Benzoxazine compounds and pharmaceutical use thereof Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 PRMT6 375/4885ALDH1A1 2654/4885SMN1; SMN2 4270/4885
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 PRMT6 1823/4885ALDH1A1 3613/4885SMN1; SMN2 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.